Interleukin-2 receptor and Interleukin-12 receptor (IL-2R and IL-12R)

Interleukin-2 receptor (IL-2R) is a heterotrimeric receptor composed of alpha (CD25), beta (CD122), and common gamma (CD132) chains, expressed on activated T cells and other immune cells. It mediates the effects of IL-2, such as T-cell proliferation, survival, and differentiation, primarily via the JAK-STAT signaling pathway[9].\n\nInterleukin-12 receptor (IL-12R) is a heterodimeric receptor composed of IL-12Rβ1 and IL-12Rβ2 subunits, expressed mainly on NK cells, T cells (especially after activation), and some B cells. It transduces signals upon IL-12 binding, leading to STAT4 activation, promoting Th1 differentiation and IFN-γ production[1][2][4][5][7][8].\n\nBoth receptors are structurally related, signal through the JAK-STAT pathway, and play critical roles in mediating and regulating immune responses, especially in cytotoxic T cell and NK cell responses. While both are distinct, IL-2 can upregulate expression of IL-12 receptor subunits, linking their roles in immune regulation[6][7].\n\nNote: For structured purposes, it is most appropriate to treat "Interleukin-2 receptor" and "Interleukin-12 receptor" as separate canonical targets due to their distinct gene products, subunit compositions, and therapeutic/biological relevance. The current query conflates them, so is_incorrect is set to true.

Other names

IL2RCD25 (IL-2Rα)CD122 (IL-2Rβ)CD132 (IL-2Rγ, common γ chain)IL12RIL-12Rβ1IL-12Rβ2

Antibody-mediated receptor blockade (e.g., basiliximab binds IL-2Rα to prevent IL-2 signaling). Receptor agonism (e.g., aldesleukin stimulates IL-2R). Neutralization of ligand (e.g., anti-IL-12 or anti-IL-23 antibodies). Cytokine-toxin fusion targeting IL-2R-expressing cells (denileukin diftitox).